Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Rare Diseases

Frailty

Leukemia

Leukemia, Myeloid

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Neoplasms by Histologic Type

Hematologic Diseases

Myeloproliferative Disorders

Bone Marrow Diseases

Chronic Disease

Disease Attributes

Chronic Graft Versus Host Disease

Myeloid Leukemia

Chronic Myeloid Leukemia

Chronic Myeloproliferative Disorders

All Drugs and Chemicals

Amino Acids

Tyrosine Kinase Inhibitors

Tyrosine

Individual biological aging determined by DNA methylation analysis will be assessed at D0, M3 and M12.

An optional bone marrow sample will be taken during the myelogram performed at diagnosis.

Individual fragility and quality of life will be assessed using geriatric tools at D0, M6, M12, M24 and M36

Blood and bone marrow sample

Lise LACLAUTRE

Mélanie CASILE, PhD

Anne PARRY, MD

Gabriel ETIENNE, MD

Atchroue JOHNSON ANSAH, MD

Marc BERGER, Pr

Melanie CASILE, PhD

Eric HERMET, MD

Clément LAHAYE, MD

Lydia ROY, MD

Vanessa PANTE, Dr

Vanessa PANTE, MD

Valérie COITEUX, MD

Amélie PENOT, MD

Jean Baptiste FARGEAS, MD

Aude CHARBONNIER, MD

Gabrielle ROTH-GUEPI, MD

Jean-Yves NIEMIER, MD

Laurence LEGROS, MD

Emanuelle DURON, MD

Martine ESCOFFRE-BARBE, MD

Philippe RENAUDIER, MD

Blandine DELAVIGERIE, MD

Françoise HUGUET, MD

Clément GAUDIN, MD

Philippe ROUSSELOT, Pr

Marc BERGER

French prospective multicenter, open-label study involving newly diagnosed CML patients. Two assessments will be performed during the follow-up of these patients: individual frailty using geriatric tools and individual biological aging determined by DNA methylation analysis.

Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated With Targeted Therapy

Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated With Targeted Therapy: the Model of Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.

The difference between biological age and chronological age (of the clone and the patient) expressed as a difference and as a percentage.

Individual fragility assessed by Geriatric Core Data set assessing social status, independence at home, mobility, nutrition, cognitive status, mood and comorbidities.

Individual fragility assessed by Rockwood clinical frailty score ranging from 1 (very fit) to 9 (at the end of life)

Tolerance assessed by actual dose received

Tolerance assessed by the number of tyrosine kinase inhibitor discontinuation due to intolerance

Tolerance assessed by a description of adverse events as assessed by CTCAE v5.0

Tolerance assessed by changes and number of tyrosine kinase inhibitor lines

Tolerance assessed by a description of treatment sequences

Individual fragility assessed by Geriatric Core Data set assessing social status, independence at home, mobility, nutrition, cognitive status, mood and comorbidities at the time of diagnosis.

Individual fragility assessed by Rockwood clinical frailty score ranging from 1 (very fit) to 9 (at the end of life) at the time of diagnosis.

Quantification of BCR::ABL transcript expressed as copy number relative to 100 copies of control gene transcripts

Decrease in residual disease and achievement of MMR (≤0.1%), MR4 (≤0.01%), MR4.5 (≤0.032%), MR5 (≤0.001%) thresholds)

Quality of life assessed using the European Organisation for Research and Treatment of Cancer LG Core Questionnaire (EORTC QLQ-C30) is a 30-item instrument designed to measure quality of life in all cancer patients, with a higher score indicating a better health-related quality of life

Spots Global Cancer Trial Database for blood and bone marrow sample